Discussion
Taxanes are considered among the most active chemotherapy agents in the standard treatment paradigm for mBC.Therefore, we performed a head-to-head randomized phase II study to compare a 3-week versus 4-week schedule of 125 mg/mTreatment scheme (In summary, this study of HER2-negative mBC demonstrated a better efficacy and more favorable safety profile for the 3-week 